Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Hikma Pharmaceuticals Ord Shs HKMPF

Healthcare
Hikma Pharmaceuticals PLC is a pharmaceutical company. The principal activities of the Company are the development, manufacture and marketing of a range of generic, branded and in-licensed pharmaceutical products. The Company operates through three segments: Injectables, Branded and Generics. The Injectables segment supplies hospitals across its markets with generic injectable products... see more

Recent & Breaking News (OTCPK:HKMPF)

Hikma marks two-year anniversary of KLOXXADO® launch by surpassing 375,000 doses donated in the US

PR Newswire October 3, 2023

Hikma confirms that it has not signed a licensing agreement with Opiant Pharmaceuticals

PR Newswire April 29, 2022

Hikma Ventures invests in Tact.ai, an AI-powered customer engagement platform for life sciences companies

PR Newswire March 29, 2022

Hikma announces US launch of KLOXXADO(TM) (naloxone HCl) nasal spray 8mg

PR Newswire August 4, 2021

Melinta Therapeutics and Hikma Sign Exclusive Licensing Agreement for Two Novel Anti-Infectives for the Middle East and North Africa Region

Business Wire April 29, 2021

Hikma resumes launch of generic Advair Diskus®

PR Newswire April 20, 2021

Sesen Bio Announces Partnership with Hikma Pharmaceuticals for the Commercialization of Vicineum(TM) in the Middle East and North Africa

Business Wire December 1, 2020

Hikma and Arecor Expand Collaboration

GlobeNewswire October 20, 2020

Hikma receives favourable court ruling for its generic Vascepa®

PR Newswire September 3, 2020

Hikma responds to COVID-19 shortage with launch of Propofol Injectable Emulsion, USP

PR Newswire May 12, 2020

Hikma launches employee matching donation campaign to support local US food banks and pantries

PR Newswire May 11, 2020

Hikma Ventures invests in Altoida, Inc., a predictive digital biomarker company using AI and AR to help predict brain diseases with up to 94% accuracy

PR Newswire May 4, 2020

Hikma confirms favourable ruling in generic Vascepa® patent suit

PR Newswire March 31, 2020

Hikma and Glenmark Pharmaceuticals Enter into Exclusive Licensing Agreement for Commercialising Ryaltris(TM) Seasonal Allergic Rhinitis Nasal Spray in the US

PR Newswire February 27, 2020

Arecor and Hikma Announce Exclusive Agreement to Develop and Commercialise Ready-To-Use Medicine Using Arestat(TM) Technology

GlobeNewswire January 9, 2020

Hikma and Arecor announce exclusive agreement to develop and commercialise ready-to-use medicine using Arestat(TM) technology

PR Newswire January 9, 2020

Civica Rx and Hikma Announce Shipments of Heparin and Seven Other Essential Injectable Medicines

Business Wire December 10, 2019

Hikma Ventures leads Series A financing for development of Winterlight Labs' AI vocal technology to detect central nervous system disorders and track efficacy of treatments

PR Newswire November 18, 2019

Hikma and Civica Rx sign long-term agreement to reduce generic drug shortages in the US

PR Newswire July 23, 2019

Hikma Ventures participates in $11 million funding round for Pillo Health

PR Newswire May 30, 2019